ÂÜÀòÂÒÂ×

Astrid Maria Dahl is an experienced executive in the biopharmaceutical industry, currently serving as Chief Operating Officer and Head of Innovent Biologics (Europe) since September 2020, where responsibilities include overseeing European operations in product development, commercialization, and business development in immunology and oncology. Prior to this role, Astrid held various leadership positions at AstraZeneca from 2012 to 2020, including Head of Transactions within the Oncology R&D division. Astrid's earlier career includes significant roles at IPSEN, Cell Genesys, and Chiron Corporation, as well as a research fellowship at Harvard Medical School focused on immunology. Educational qualifications include an MBA from the University of California, Berkeley, a Ph.D. in Tumor Immunology from UCL, and an MSc in Chemical Engineering from the Technical University of Denmark.